A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help with weight.
- Who can join
- Children and teens 6 to 17, have obesity.
- What you take
- orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 2.3 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Full study title: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040).
Primary condition: Obesity. Also studied in: Overweight.
Who can join, in detail
Key inclusion criteria
- Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.
- Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022]); OR
- Applies to participant age between 12 and <18 years old. Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,
- hypertension
- type 2 diabetes (T2D)
Key exclusion criteria
- Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:
- gastric bypass
- sleeve gastrectomy
- restrictive bariatric surgery, such as Lap-Band gastric banding, or
- any other procedure intended to result in weight reduction.
Where this study is enrolling
This trial has 16 US sites across 13 states. Contact the site coordinator directly to start the screening process.
California
- Carey Chronis MD Pediatric, Infant and Adolescent MedicineVentura, California805-642-4704
Connecticut
- Yale School of Medicine - Yale Diabetes Center (YDC)) TrialsNew Haven, Connecticutania.jastreboff@yale.edu
- Stamford Therapeutics ConsortiumStamford, Connecticut727-544-4842
Georgia
- Children's Healthcare of Atlanta - Center for Advanced PediatricsAtlanta, Georgia404-712-4731
Illinois
- Ann and Robert Lurie Children's Hospital of ChicagoChicago, Illinois312-503-1499
Louisiana
- Velocity Clinical ResearchLafayette, Louisiana337-519-4742
Mississippi
- Dynamed Clinical Research, LP d/b/a DM Clinical ResearchGulfport, Mississippi228-206-1283
Missouri
- Sundance Clinical ResearchSt Louis, Missouri314-567-3377
Nebraska
- Velocity Clinical ResearchOmaha, Nebraska402-933-6500
North Carolina
- Lucas Research, IncMorehead City, North Carolina252-222-5700
Pennsylvania
- UPMC Children's Hospital of PittsburghPittsburgh, Pennsylvania412-692-6935
Tennessee
- Vanderbilt Health One Hundred OaksNashville, Tennessee615-322-6000
Texas
- Dynamed Clinical Research, LP d/b/a DM Clinical ResearchHouston, Texas281-517-0550
- La Providence Pediatrics Clinic - Chemidox Clinical TrialsHouston, Texas833-324-3643
- Martin Diagnostic ClinicTomball, Texas281-517-0550
Utah
- Velocity Clinical Research, Salt Lake CityWest Jordan, Utah801-542-8190
Timeline
Started enrolling: 2024-11-18. Expected completion: 2027-03. Last updated on ClinicalTrials.gov: 2026-05-19.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.